Navigation Links
Low cholesterol in immune cells tied to slow progression of HIV
Date:4/28/2014

PITTSBURGH, April 29, 2014 People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public Health research that could lead to new strategies to control infection.

The Pitt Public Health researchers found that low cholesterol in certain cells, which is likely an inherited trait, affects the ability of the body to transmit the virus to other cells. The discovery, funded by the National Institutes of Health (NIH), is featured in today's issue of mBio, the journal of the American Society for Microbiology.

When HIV enters the body, it is typically picked up by immune system cells called dendritic cells, which recognize foreign agents and transport the virus to lymph nodes where it is passed to other immune system cells, including T cells. HIV then uses T cells as its main site of replication. It is through this mechanism that levels of HIV increase and overwhelm the immune system, leading to AIDS. Once a person develops AIDS, the body can no longer fight infections and cancers. Prior to effective drug therapy, the person died within one to two years after the AIDS diagnosis.

"We've known for two decades that some people don't have the dramatic loss in their T cells and progression to AIDS that you'd expect without drug therapy," said lead author Giovanna Rappocciolo, Ph.D., an assistant professor at Pitt Public Health. "Instead the disease is much slower to progress, and we believe low cholesterol in dendritic cells may be a reason."

The discovery was made possible by using 30 years of data and biologic specimens collected through the Pitt Men's Study, a confidential research study of the natural history of HIV/AIDS, part of the national NIH-funded Multicenter AIDS Cohort Study (MACS).

"We couldn't have made this discovery without the MACS. Results like ours are the real pay-off of the past three decades of meticulous data and specimen collection," said senior author Charles Rinaldo, Ph.D., chairman of Pitt Public Health's Department of Infectious Diseases and Microbiology, and professor of pathology. "It is thanks to our dedicated volunteer participants that we are making such important advances in understanding HIV, and applying it to preventing and treating AIDS."

Medications called combination antiretroviral therapy (ART) disrupt the viral replication process and can delay the onset of AIDS by decades.

However, even without taking ART, a small percentage of people infected with HIV do not have the persistent loss of T cells and increase in levels of HIV after initial infection. They can sometimes go many years, even more than a decade, without the virus seriously compromising the immune system or leading to AIDS.

Through the Pitt Men's Study/MACS, eight such "nonprogressors" were assessed twice a year for an average of 11 years and compared to eight typically progressing HIV-positive counterparts.

Dr. Rappocciolo and her colleagues found that in nonprogressors, the dendritic cells were not transferring the virus to T cells at detectible levels. When taking a closer look at these dendritic cells, the researchers discovered that the cells had low levels of cholesterol, even though the nonprogressors had regular levels of cholesterol in their blood. A similar finding was shown for B lymphocytes, which also pass HIV to T cells, leading to high rates of HIV replication.

Cholesterol is an essential component of the outer membranes of cells. It is required for HIV to replicate efficiently in different types of cells. None of the study participants were taking statins, which are cholesterol-lowering medications that some people take to prevent vascular problems when cholesterol in their blood is too high.

When HIV was directly mixed with the nonprogressors' T cells in the laboratory, those T cells became infected with the virus at the same rate as the T cells of the regularly progressing, HIV-positive participants. Indeed, T cells from the nonprogressors had normal levels of cholesterol.

"This means that the disruption is unlikely to be due to a problem with the T cells, further supporting our conclusion that the slow progression is linked to low cholesterol in the dendritic cells and B cells," said Dr. Rappocciolo.

"What is most intriguing is that dendritic cells in the nonprogressors had this protective trait years before they became infected with HIV," Dr. Rinaldo said. "This strongly suggests that the inability of their dendritic cells and B cells to pass HIV to their T cells is a protective trait genetically inherited by a small percentage of people. Understanding how this works could be an important clue in developing new approaches to prevent progression of HIV infection."


'/>"/>

Contact: Allison Hydzik
hydzikam@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert  

Related biology news :

1. Study finds cancer-fighting goodness in cholesterol
2. Some HDL, or good cholesterol, may not protect against heart disease
3. Zebrafish research shows how dietary fat regulates cholesterol absorption
4. Vitamin D supplements do not improve cholesterol as previous research suggested
5. Host cholesterol secretion likely to influence gut microbiota
6. Cholesterol helps regulate key signaling proteins in the cell
7. Study identifies liver gene that regulates cholesterol and fat blood levels
8. Researchers find alternative cholesterol-lowering drug for patients who cant tolerate statins
9. Cholesterol rafts deliver drugs inside cancer cells
10. U-M researchers find new way to clear cholesterol from the blood
11. 4 genes indentified that influence levels of bad cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Low cholesterol in immune cells tied to slow progression of HIV
(Date:5/21/2020)... ... 21, 2020 , ... Agility Orthopedics, home to dedicated specialists ... is pleased to announce a partnership with Dallas-based Simple Interact to further enhance ... area, Agility Orthopedics is focused on speeding up patient workflows to enhance patient ...
(Date:5/11/2020)... ... May 11, 2020 , ... Octagos Health, a Houston-based ... implanted cardiac devices. The Octagos software allows healthcare professionals access to cardiac patients’ ... the management of remote transmissions and at the same time provides real-time patient ...
(Date:5/1/2020)... ... , ... InBios International Inc., a leading developer of diagnostic ... contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the ... of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG Rapid Test, ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... 2020 , ... Early stages of drug discovery often depend ... on the drug’s mechanism of action (MOA). Gene expression profiling technologies like RNA ... of molecular pathways. This information can complement phenotypic readouts and can be used ...
(Date:5/5/2020)... YARDLEY, Pa. (PRWEB) , ... May 04, 2020 ... ... performance, and process solutions for the life sciences industry, today announced that Informa ... 2019, is officially changing its name to Red Nucleus Boston, effective immediately. , ...
(Date:5/5/2020)... ... 2020 , ... Smart Meter, a diabetes management ... LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor and Remote Patient Monitoring ... broadest cellular connectivity available, to provide patients with seamless connectivity to their physicians ...
(Date:4/26/2020)... ... April 23, 2020 , ... Indegene Omnipresence, Inc. ... providing applications and services for use on Microsoft Azure. The customer experience management ... up online for a built-for-purpose customer engagement capability to use in their commercial ...
Breaking Biology Technology: